The pharmaceutical industry is witnessing a significant surge in the development of novel drug screening technologies, with a particular emphasis on DNA-encoded libraries (DEL). This technology allows researchers to explore vast chemical spaces, identify potential drug candidates, and accelerate the discovery process. In this context, the strategic collaboration between Chemspace, Enamine, and Orogen Therapeutics is set to revolutionize the field of drug discovery.
Chemspace, an expert in generating and exploring ultra-large chemical datasets, and Enamine, a leading provider of chemical compounds and drug discovery services, have partnered with Orogen Therapeutics, a private drug discovery company utilizing its proprietary DEL technology to identify novel chemical matter against medically and commercially attractive drug targets.
Enamine’s REAL Space: A Vast Chemical Library
Enamine’s REAL Space is the world’s largest collection of make-on-demand small molecules, representing a significant fraction of the synthetically accessible chemical space. Its member molecules are REadily AccessibLe through validated parallel synthesis protocols using qualified in-stock building blocks. This vast chemical library provides an unparalleled opportunity for DEL-based drug discovery.
“We are thrilled to engage in this strategic collaboration to drive new horizons for DEL-based drug development,” stated Mark Pykett, Orogen CEO. “We are excited by the potential synergy of the two platforms to enhance and accelerate small molecule drug discovery.”
DEL Technology: A Power Tool for Efficient Drug Discovery
DEL technology enables rapid, efficient drug screening of billions of chemically diverse compounds to effectively identify small drug-like molecules against specific targets from a wide range of therapeutic areas and clinical indications. The partnership between Chemspace, Enamine, and Orogen will leverage this technology to accelerate the discovery process.
“DNA-encoded library (DEL) screening offers a proven valuable alternative for sampling large chemical space for efficient small molecule drug discovery,” stated Sven Wagner, PhD, Vice President of Partnerships at Enamine. “We are pleased to bring our large and rapidly synthesizable Chemspace/Enamine chemical space into this collaboration with Orogen, a pioneer in DEL-based drug discovery.”
Collaborative Approach: A Win-Win Situation
Under the terms of the collaboration, Chemspace and Orogen will design novel DELs in alignment with the REAL Space foundational principles. Chemspace and Enamine will synthesize and analytically validate these REAL-driven DELs, and Orogen will screen pilot DELs against multiple biological targets.
“We anticipate this collaboration will add a set of much-needed next-generation DELs to the arsenal of early drug discovery tools,” stated Artem Evdokimov, PhD, Orogen’s head of research. “Harmonization of DEL designs with REAL space chemistry enables rapid follow-up on screening: off-DNA compounds and thousands of their SAR-expanding chemical space neighbors can be made both expeditiously and economically.”
Benefits of the Partnership
The collaboration between Chemspace, Enamine, and Orogen will bring several benefits, including:
- Enhanced DEL-based drug discovery capabilities
- Access to a vast chemical library through Enamine’s REAL Space
- Increased efficiency in drug screening and discovery
- Accelerated development of novel small molecule candidates
Conclusion
The strategic collaboration between Chemspace, Enamine, and Orogen Therapeutics is set to revolutionize the field of drug discovery. The partnership will leverage DEL technology, Enamine’s vast chemical library, and Orogen’s expertise in DEL-based drug discovery to accelerate the discovery process. As the pharmaceutical industry continues to evolve, this collaboration is poised to play a significant role in advancing the development of novel drug candidates.
